[{"title": "Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights - GlobeNewswire", "description": "<a href=\"https://news.google.com/rss/articles/CBMi8wFBVV95cUxNb3BjZnJBZkVrWmFxREpha1FPYmxaelNMTTJGb2hVaXhnaFNxS0ZvOFN0bFNjR0pmbEw4b1JPQ1kxMGliVVVlN0lCQWNuX0tiMUwydmZtQWRabzJ5UkxNWXd4NmtocUc2N0lZekJZUHc2Y3dFMlFZckpkdHJZNFl6YVEyZktGd2VnR0NPY2Q4cWxQcWJGLUF4Y2xwSVdmZ2Z1Rzhxc2NNTnhaNW9vd0pZdUxVU0FKMzVXaVdyWDgzSnNYVVRnUDFIRlV1Q3RBQ1BFN3RoZE1fVF9ULWFHa041blNSdWVaRm5wOXdBcnJheTZ4TEU?oc=5\" target=\"_blank\">Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">GlobeNewswire</font>", "publishedAt": "Thu, 14 Aug 2025 20:16:57 GMT"}, {"title": "Plus Therapeutics Turns Profitable as New Cancer Detection Tool Readies for Launch - Stock Titan", "description": "<a href=\"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOU01ySGt1WXlVaTc0cVVucVdPTXBsRS1Ea0RGREZOMGV1VEdjdVhiOFY5MHY5NnFmcVU1bTlJazRPaktqWi1FWmpMVXVDNlBRY3l1ZEJubmdJbm9rQzB6LVJmbzNQREtYM2RtV0lWWUJQa2h0dDZrYlEwMzdIUHc2RVdLLXJpRk11RXB4TWgxNUhsTDFGQTRfNW5SN0VhX1JNeTE5UkNydkY4Wk9FbmhORTRrZjE3TGln?oc=5\" target=\"_blank\">Plus Therapeutics Turns Profitable as New Cancer Detection Tool Readies for Launch</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Stock Titan</font>", "publishedAt": "Thu, 14 Aug 2025 20:15:00 GMT"}, {"title": "Plus Therapeutics receives extension to meet Nasdaq listing requirements - Investing.com", "description": "<a href=\"https://news.google.com/rss/articles/CBMixwFBVV95cUxOMnVEbkVjOTRLYURfdUNXSE5ILXdkWGhialM5WUdDNW5SYTlvTm9GRmx2bktJbWQzc0RLdW9ObkNuSEhjZm9UeV9GMVJ3aEkwS1FEYlVjU3ZHRm9wakkxRTlwdTBNOVpqMnlOMjRyRTF0d1g0RUFMWWRKT21OVWsyR2xGYU45V2RUSEk2T0pETWpQN09YU1Q5Sl8ybWR3TUpUQ0JFSlR6dTlaT18zNWtWMVl4d2tlSHZWazNYTDVQdmxHcXR4WFhr?oc=5\" target=\"_blank\">Plus Therapeutics receives extension to meet Nasdaq listing requirements</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Investing.com</font>", "publishedAt": "Wed, 13 Aug 2025 10:35:51 GMT"}, {"title": "Plus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates - Nasdaq", "description": "<a href=\"https://news.google.com/rss/articles/CBMimwFBVV95cUxPal8tOEVKUXdxOU9hYUVYb0F4Ulh5aEpXUGRHakpYWmh5UXcxbkxQX2VXd3o5QVA2bm5GZnlmUmRKanFnYkgyX2VkSVkyR1FkQXJlX25FeDROb3o3SEVGc053QjhOSHQyZ25acEZsNU9Ub3NvemR5QzRyVlNTb3prUFM2TU9TalB0TjdoOWpEdkFFODBoOFNLZl9IUQ?oc=5\" target=\"_blank\">Plus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Nasdaq</font>", "publishedAt": "Thu, 14 Aug 2025 21:30:00 GMT"}, {"title": "Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingView", "description": "<a href=\"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPSFpnTTZ2bmgxdllfaGNoMmZhY1Y1NmxrbDV0bkdRSzMzMzB1WmdtMlZ0Q0xMRmZIa0lMbTlGVm1SRWdfRDBaczVDN0hvRnYzcnc3b1I3TFNPOUNaeU5XRW9tOVU5ZW9kczNnbkFaelc4RW1ocGlhUnlDay1XSms2OW40c1dzZ0VPYzBNRXQzaW11Uk92OF9EMm5WUEFPVTlGVUVfZzJESERiS3luQmxIUjJSYnhLd2h4NjhXNHdPRDI0OXZjVUJHZU44NzEzZGYtNmlKdUlRWGswR0h3WkVtWkxXMUt4SERaZnc?oc=5\" target=\"_blank\">Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TradingView</font>", "publishedAt": "Thu, 14 Aug 2025 21:41:44 GMT"}, {"title": "Plus Therapeutics Granted Continued Nasdaq Listing with Conditions - AInvest", "description": "<a href=\"https://news.google.com/rss/articles/CBMilgFBVV95cUxNODc1UWdDeHdQX0RhakJKWkdWcElmOG1Iemc4YU1WQXIzX0c3MEREZVdpS3BiZGZrM29MT2pmNHdpbUd6TTkzdGJ0RDllX0ZOd2htOUt3WTJzV0JaM19GdnpZY3YzeERidU5ZaTl6TGtHalpGV1R2Yk1hLUpTQldrS1R4QnZPbkkzQ2c0NFMxZ05hWllkX1E?oc=5\" target=\"_blank\">Plus Therapeutics Granted Continued Nasdaq Listing with Conditions</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">AInvest</font>", "publishedAt": "Thu, 14 Aug 2025 01:35:42 GMT"}, {"title": "Plus Therapeutics Approves Key Proposals at Annual Meeting - TipRanks", "description": "<a href=\"https://news.google.com/rss/articles/CBMirwFBVV95cUxQWkRveVdhN1JGY045ekR1eXo4UlktbEdrMEJsbWdKaUhPUGlsMmZtX3lyVHhqSTJ1NGlvMkVmT3d4cWhRQkVkZzB5c0k4aDFUSEFVZElwWk5VeXZOYlQxdGFXa0NIU2hCS3JDV05hUXAwQ2U3Z1B4RXlxVXdsTlRNVHdJWUNaS2l5Wm96WjhxMnoxSjJxRTFIRGNJa05iemdqS3lrYmstY0QwQXBTU0JB?oc=5\" target=\"_blank\">Plus Therapeutics Approves Key Proposals at Annual Meeting</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TipRanks</font>", "publishedAt": "Tue, 12 Aug 2025 21:21:01 GMT"}, {"title": "Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights | PSTV Stock News - GuruFocus", "description": "<a href=\"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPZXIwNFFnU1pkMnp1TmI0eUZlYmZQRllXN1B6WGVWS0lJLVRyMnlDOG1oNDZYMHA3Q18tY3VOSTU5akJJWDNMbUdZamtPSmJYSElIUzd2VFhLMkNRR0VGZ0J6eTl6TlJhMU9XNlNaeWtqWjJvMV9SV09qZWlNVkpEUk1ZQzhoTDNBck9NeVJsS2lNVUk4c2txXzViakxDdl9hZU5Vdy1hWHNneWNYMWhDMU9xcFRJWU9WQlhVWlpUQlJ0bzBUanRIODdkY0l3TVowa3NCSnVMNnNMRnFx?oc=5\" target=\"_blank\">Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights | PSTV Stock News</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">GuruFocus</font>", "publishedAt": "Thu, 14 Aug 2025 20:36:58 GMT"}, {"title": "Plus Therapeutics Reports $3M in Stock Equity - Baystreet.ca", "description": "<a href=\"https://news.google.com/rss/articles/CBMikwFBVV95cUxQWmRiYzFsaWZQYjB6aHRxQ3lqVm9sU1JkdjhkTU92R2xnZ2tmb3FPM2pUTGNPU0o2QkJDc0xBVlpwY1oweXBObGtzZmU0anAtcWNHODVpSHhtSnJYU1BuRkU0UmI1RWtlSGt3Z1JDXzdFYWVGMmtPOXRVSllVLTVrMkFjdmdMbHNydy1iV3ZSeGNyOVnSAX5BVV95cUxNVVhxT0tJNlZ5aWdrcE5qcFpfcE44TEw3NEpKOGlFSVdLXzdUUmZHR3VHbnVjNHlZa3JtRXRrblZXOGFhLUVjSzdydHdwdW0tZjlsVWVwUUJhWkU1Q0djUmdNQlp3YjZ4UzcyYWtZM1dsOGJzcEpRcnFzSmJiY0E?oc=5\" target=\"_blank\">Plus Therapeutics Reports $3M in Stock Equity</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Baystreet.ca</font>", "publishedAt": "Fri, 15 Aug 2025 13:46:00 GMT"}, {"title": "Plus Therapeutics Reports Stockholders\u2019 Equity in Excess of - GlobeNewswire", "description": "<a href=\"https://news.google.com/rss/articles/CBMilwJBVV95cUxPSlFqazhhdV8wdnZ6Z2diNVpQY3VxSDJPSTNzV0JVWUZjWGtUaEJ6dy1oN2o3bjU0TmxiZkktZ2NuT25Zai1TN2NndVI4TzhEMkVZX1BqbFU2MDlGUGpLREExR2s3d3pnN19fQ1ViTS1NSUVLNDZwNUZ6VHktcjVWQnlKUW14ampkMS1FQVRqWmg1Um5oTmlvNV9oS3pwR1M1ZDZQVVA3SVZrZ29UcTR6dGtGTW5qRktCcER0Q2lnM3VDaDFTNml3Xy1QYVJiR01tNkh1NFVqNU5TY0FpQTV1eFNoWjhVcnJwY3JoeGJOX0ZyaWhVTHlaWkxvdldvY3pYaDNpbWpMVDlJZVhiOXNJbmJSeXpsZ3M?oc=5\" target=\"_blank\">Plus Therapeutics Reports Stockholders\u2019 Equity in Excess of</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">GlobeNewswire</font>", "publishedAt": "Fri, 15 Aug 2025 11:31:21 GMT"}, {"title": "$3M Equity Achievement: Plus Therapeutics CNS Cancer Drug Developer Maintains Nasdaq Listing Status - Stock Titan", "description": "<a href=\"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOUmRTNVNQOFJrVDFsVF85V0dodjV0SUljdmp1NC05aWpnRUpYQkZVLVlmV3FicFN0TU1mRnNjZHZwaUxUV2c2Q1lUcUtTdkM3WUJFS1QwZXVnTGJyZHFLV19rVnBwVzB6dDM5WWZHS0JJdjlVbC1yYTZDaGRYTG5FZWRGaUxPaThFWU8zbTBmLWxrSUhyUm1xWFBlS0ZIRnJrVGRPdGJhUEkzU292X2ttS3hWVDRvWlBX?oc=5\" target=\"_blank\">$3M Equity Achievement: Plus Therapeutics CNS Cancer Drug Developer Maintains Nasdaq Listing Status</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Stock Titan</font>", "publishedAt": "Fri, 15 Aug 2025 11:30:00 GMT"}, {"title": "Plus Therapeutics meets Nasdaq equity requirement to maintain listing - Investing.com", "description": "<a href=\"https://news.google.com/rss/articles/CBMixAFBVV95cUxOeFRSTDhjVk1LcDZrVHJVZmtDQktxNktTNTZ5VEpXRkJFNXBQQ1VJVFd2S1I0WGYwMlhmYW85YVJjeFh4M0plaFNwM0FIc1NXalMyU1gwU2dvQV9wcWsxMXdJOWVTcUVuQThQc05FY21aS011enMxQVN3RTd1bDVPSHhHaThwREI5T3RuRndOd1pLZkNMb21JTkNnMWljQVpYamUydlRpTzBHcHRHdDRwRGdlak5Mc3gtRHY5a2JaVV95ZVRp?oc=5\" target=\"_blank\">Plus Therapeutics meets Nasdaq equity requirement to maintain listing</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Investing.com</font>", "publishedAt": "Fri, 15 Aug 2025 11:52:21 GMT"}, {"title": "Plus Therapeutics Reports Strong Q2 2025 Results - TipRanks", "description": "<a href=\"https://news.google.com/rss/articles/CBMiogFBVV95cUxOLWR6bWlUaWJpUjVQdzcxZ3l6V0VwZWRsbGlEMFBhMnVpOVFkbUxiZkNEUGVyT0oyUXA3SmdVQzZmQWI0QVRERlFMM1hmc01zbUQwT3hJTkFrSG8wTEhJQ3VOdVJvWE9lTW8yblNNZUI1bm1MdUNQd0txMWd6UjJTXzNLUEFzaVBWd3kzLWY4RTJSd09fd3lrcDB3cDljd2RYTGc?oc=5\" target=\"_blank\">Plus Therapeutics Reports Strong Q2 2025 Results</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TipRanks</font>", "publishedAt": "Fri, 15 Aug 2025 05:10:22 GMT"}, {"title": "Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference - Yahoo Finance", "description": "<a href=\"https://news.google.com/rss/articles/CBMikgFBVV95cUxOclI4Uzdaanl0TklPM2phSFQzUEhBSG5Jc0JscmpZZHoyNF9KN3V6VGd6Vy1uMXg3eDVtaTNIdUdJNno4akFSYXhwLWk0YUxyZEVPU0E5aWgySlFqMHJaV21QOTJielN1VWN5N0ZLeTVFVGpucl9oTk9MdGlhOUJwYVJhOFM3cFhERVJFc1NrMDRRZw?oc=5\" target=\"_blank\">Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>", "publishedAt": "Thu, 14 Aug 2025 11:30:00 GMT"}, {"title": "Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements | PSTV Stock News - GuruFocus", "description": "<a href=\"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNUjNyVjNlSmN3VWtjZEJpTE9OUnhoakxpYzh2ZWpPamxrQXVPQ0R2RUlLaEJvZVJrX2FoT0lZdDNrRVJaUld2bGZWcDREZTF1cjMxc0llMnNYbUwzREVIT0p2UEt5bm1TM21BQ2tHdjhTVzVNN0lUODQ3LXNlWHlLd1FUYjhUeWs3Tlg0SEpLX09LZWdPS1c0Nnd6QWhVTURUWWtJdTBzS0RiUk1xbWNfTUZSMXN3WEhuNzI4U2J0X2l5dnhSdW9uazF1T1NRbF9OQ3BwcnEzT2xFck1QRW12SEpnUmRVTG5idkdfR2Y2ZnE1S2dZVVk1SnNpWDZiQQ?oc=5\" target=\"_blank\">Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements | PSTV Stock News</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">GuruFocus</font>", "publishedAt": "Fri, 15 Aug 2025 11:45:45 GMT"}, {"title": "Plus Therapeutics Approves Key Proposals at Annual Meeting - MSN", "description": "<a href=\"https://news.google.com/rss/articles/CBMisgFBVV95cUxOSi1vdGZ5QkxFNjhSRzVaUXdfN21Db3pzQVlyM1FDcXZWemh6cnZSNERHQVRuOXpxZTNrRlpEaDdweWNVWndGaUFQUXIwWUxRUldhTmhjcDF3R2U1QThqUUxxX1NMNnlQaEhWZnRKX3RISm9QQldqTVZfakp2Qm5vVi1wRkxMeE41VUVYd3U1a2tidW9LcnRXeEZSTTlMbHVwYTVDWlhmUE5ac2ZSU1p4QzZB?oc=5\" target=\"_blank\">Plus Therapeutics Approves Key Proposals at Annual Meeting</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">MSN</font>", "publishedAt": "Fri, 15 Aug 2025 13:18:00 GMT"}, {"title": "Plus Therapeutics Approves Key Proposals at Annual Meeting: A Strategic Move to Strengthen Financial Position and Operational Flexibility - AInvest", "description": "<a href=\"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQTmVVN0UzNlphU3I1ZlQ0SGF4TVpwV2d6MFdBNlZpWmNSZEtkX0JSaXlETE9PTS1KYzdJYnNDSUprNEdzbTlWakhtMW9FOXVIc1NpUDdDUjdLU2JCT3h6U2o1blhHZjljTTBmQWNXdWRvelA4WXNQS0tSU050NGRTUVZQZWtDdi1FZnM5VTZCV2tkUUdCY3VvcTlJQ2tPbVUzUTJGcS10aFE2WEwyRi11cG4wcnBmWkR1TDdCMVhaV0ZMYWRrZGZ3WWxBZzc0M0E5OGI3R09SdVVrWGs3UVY1dWpodVF2dzZMZWc?oc=5\" target=\"_blank\">Plus Therapeutics Approves Key Proposals at Annual Meeting: A Strategic Move to Strengthen Financial Position and Operational Flexibility</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">AInvest</font>", "publishedAt": "Wed, 13 Aug 2025 02:24:22 GMT"}, {"title": "Plus Therapeutics shares fall 6.79% intraday after presenting positive CNSide CSF Assay data. - AInvest", "description": "<a href=\"https://news.google.com/rss/articles/CBMitgFBVV95cUxNdlZkSFA2OFpBYjl6SFdRbFRrSVVNMDVQN3J2SE1Rei1qeFNQbVB1WmFDZWhVTzBJc0xwemkxTy1wRndmdjdoS19RM2lVRzRSNHE1eXc2MzVpYXNVNWJOV3NDZmpzVjBORS1ZMnA2ckV1dmFWUUtHWEhKOXFxLVdtdldlNFJuZDJmYnJianJGMjk2bnZjTV9VbEMybU5aZno4S2VGeTZ4YkUyTlM4NVB5UVhZWnlBUQ?oc=5\" target=\"_blank\">Plus Therapeutics shares fall 6.79% intraday after presenting positive CNSide CSF Assay data.</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">AInvest</font>", "publishedAt": "Thu, 14 Aug 2025 17:07:17 GMT"}, {"title": "What\u2019s the recovery path for long term holders of Plus Therapeutics Inc. - Trade Analysis Summary & Capital Efficiency Focused Strategies - Newser", "description": "<a href=\"https://news.google.com/rss/articles/CBMisAFBVV95cUxOb1ZibFJRZ0RjWE5zSTVFa25DZXRzSThITm5BNEJWTHhaajRYeHhtbTVqbG15TVdpM0M2RnktYXRUNk5NNmQyTXl6aHg2OHdqOERKM0hzU2pIR3Z1WVM0eUZabDhwOWl5cDZlQjFZYXNaMnhNYnVhZ1g3QXNrcTB5NndXYVliQ1FCZmNLUm5reFVrV1RSV1pKZG42d1NxM19iRlYxOHFnZ1BSUFo2WnFnTw?oc=5\" target=\"_blank\">What\u2019s the recovery path for long term holders of Plus Therapeutics Inc. - Trade Analysis Summary & Capital Efficiency Focused Strategies</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Newser</font>", "publishedAt": "Fri, 15 Aug 2025 20:17:16 GMT"}, {"title": "How sentiment analysis helps forecast Plus Therapeutics Inc. - July 2025 Spike Watch & Free Reliable Trade Execution Plans - Newser", "description": "<a href=\"https://news.google.com/rss/articles/CBMimgFBVV95cUxPTzVTcWpYX0ZHeWNpQzdIbTF1cmU0ay1rMUJFT0daWkREUV90UXJTNmVXcUNFTU9VNlltWDJHaDZiRUo1eml3YlZ5SGt4RW9YdjFTYzhsbkgzVFAzZzhCMDEyTFZsc2c0T0Fhc3BrcUdjU0xnWUF4VDQ1Ml9wQ1diQWsxLWRUSjJmdmpoX3AwT3lVRTR1bnZrd3dR?oc=5\" target=\"_blank\">How sentiment analysis helps forecast Plus Therapeutics Inc. - July 2025 Spike Watch & Free Reliable Trade Execution Plans</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Newser</font>", "publishedAt": "Wed, 13 Aug 2025 11:41:19 GMT"}, {"title": "Backtesting results for Plus Therapeutics Inc. trading strategies - July 2025 Update & Accurate Intraday Trading Signals - Newser", "description": "<a href=\"https://news.google.com/rss/articles/CBMimwFBVV95cUxOMTV6VGdZZVpCWVpmbG96NDM3eXZIOG9uMUphRnpHSDdMa3lFWjlvNVE1alJDZG1GVVg4Z3lsd0E3d3lINFFCaVY2Z3pGMnhtZ0stQnlHLVJoSDd6MDBObXZEWGxJVTJXNEx6VDktczh5MlZhMmtSY043SnN6eUFnNnJlaUpVckpWdDVCMWFxczdadUtRNUlydG1aZw?oc=5\" target=\"_blank\">Backtesting results for Plus Therapeutics Inc. trading strategies - July 2025 Update & Accurate Intraday Trading Signals</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Newser</font>", "publishedAt": "Fri, 15 Aug 2025 10:56:17 GMT"}, {"title": "Competitive Positioning of Plus Therapeutics Inc.: Is It Leading or Lagging - Capital Growth Summary Over Five Years - Newser", "description": "<a href=\"https://news.google.com/rss/articles/CBMipwFBVV95cUxOY3VzRzVFaEpjeW45aW5ZRERxOXdhaGF1M09PQlpKZW5rRHpwV2RLcTJlTFV1SmR2ZnhOMmZIeWdvQjJSeDRmVFg1WjQzSVl5cTlSN3RkZXhUQ3JJYlVjUGZoOEU2RmtGMUc1WTZIQkNCa2dZelZHUC1JZ3ItWFJCN2Nkb1V5YVdUSlZOMGpZYlFDSVloRHgxWVhJd3prOWRxS1dITjVNMA?oc=5\" target=\"_blank\">Competitive Positioning of Plus Therapeutics Inc.: Is It Leading or Lagging - Capital Growth Summary Over Five Years</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Newser</font>", "publishedAt": "Mon, 11 Aug 2025 07:28:17 GMT"}, {"title": "Plus Therapeutics Inc. stock trend forecast - July 2025 Sentiment & Long-Term Safe Investment Plans - Newser", "description": "<a href=\"https://news.google.com/rss/articles/CBMifEFVX3lxTE5EdnNUOHZpZXh4cUlaeXBIWEltQ2U4a0Z0LUNycnhDWWtPaUt2ei1rblBpbjRRMHpIbm1WbGNYOVNIN0xyS3hmaGpuYkY2YUtnZE40WUtwRE82Nm9McVRMNXIzb1Zpc1hibkMzRmdrQ21NOUpzQkNXa1F0NXY?oc=5\" target=\"_blank\">Plus Therapeutics Inc. stock trend forecast - July 2025 Sentiment & Long-Term Safe Investment Plans</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Newser</font>", "publishedAt": "Wed, 13 Aug 2025 11:02:19 GMT"}, {"title": "Using Python tools to backtest Plus Therapeutics Inc. strategies - 2025 Major Catalysts & Reliable Entry Point Trade Alerts - Newser", "description": "<a href=\"https://news.google.com/rss/articles/CBMimAFBVV95cUxQMndyYUl6YTN4bzJSY29RazhzcFg4QmI0Y204Nk5ac1U3dDVKNFZTem5xeHZSbE1adGFCY0tENjBYbEt3VHAtd2l0U3dnV0RGaHpGT3lxTXJpdS1kVjAyanRscHNUWk8wVXYxUHZOLWgtTmphbHQtVEdzSGZubVd1VjNyQ0J4Snp2SjRWcF8ySGprT2lxM0VHWQ?oc=5\" target=\"_blank\">Using Python tools to backtest Plus Therapeutics Inc. strategies - 2025 Major Catalysts & Reliable Entry Point Trade Alerts</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Newser</font>", "publishedAt": "Fri, 15 Aug 2025 09:41:02 GMT"}, {"title": "How Plus Therapeutics Inc. stock performs during market volatility - Free Market Entry and Exit Point Tips - Newser", "description": "<a href=\"https://news.google.com/rss/articles/CBMilgFBVV95cUxPLUJncjNKcmc4a2ZGTEZUQ0NGVlZ1RUtsQVdWbXlERkVJdTBwYkp1b1BCbVJKQXZraUxRYjloLUYyblpTMFd6QlBoam55bkN5aVBDYmljV3d5bVdPRXJTZ2NlYm1LbENJcm1HU1c0MkhHUmlST25vYWJ2SXZlcUk3YU1fbU44QldzVzlRZ3BlTTNYSWU5TEE?oc=5\" target=\"_blank\">How Plus Therapeutics Inc. stock performs during market volatility - Free Market Entry and Exit Point Tips</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Newser</font>", "publishedAt": "Mon, 11 Aug 2025 01:13:23 GMT"}, {"title": "Plus Therapeutics (PSTV) Projected to Post Earnings on Wednesday - Defense World", "description": "<a href=\"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPRlkwQllVWXpPejFwVXowSEN0OUNNQ05tRGRKYmJ4Vi1STm92UmJrQTRVaUt1eUlsVGNkY0duQ3R4ZnFOX3Fva0NwVWlreXYtN1hkc2x1QzJvNm5ZOGNDWERLb1dvRDNna3ZpT2swbHdReVFiNGRrVkVRSWpxZEdGZ0loNno3UmtXYUhoazUwNTF4TmxJYVB1LVdyNklsSzliWjM1Njh1ald5S1U?oc=5\" target=\"_blank\">Plus Therapeutics (PSTV) Projected to Post Earnings on Wednesday</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Defense World</font>", "publishedAt": "Tue, 12 Aug 2025 06:30:51 GMT"}]